Please assess the completion status of the following clinical trial:

Trial Title: IMT for Primary Clostridium Difficile Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diarrhea as defined by the World Health Organization (passage of 3 or more loose or liquid stools (i.e. taking the shape of the receptacle or corresponding to Bristol stool chart types 5-7) per day, or more frequently than is normal for the individual, and~* Positive fecal test for toxigenic Clostridium difficile, and~* No evidence of CDI during the previous year.~Exclusion Criteria:~* Known presence of other stool pathogens known to cause diarrhea.~* Pregnancy and nursing.~* Patients with ongoing antibiotic treatment for other infections that cannot be stopped for at least 12 hours.~* Inflammatory bowel disease.~* Patients incapable of providing informed consent.~* Patients with \<3 months life expectancy.~* Serious immunodeficiency caused by chemotherapy or other medication.~* Active immunocompromising disease.~* Patients unable to comply with protocol requirements.~* Patients in need of intensive care who are American Society of Anesthesiologists (ASA) Physical Status classification IV and V.~* Known hypersensitivity to Metronidazole

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intestinal microbiota therapy (Type: EXPERIMENTAL): The patients allocated to this group will receive 60 ml of the anaerobically cultivated human intestinal microbiota through a rectal catheter.
- Metronidazole (Type: ACTIVE_COMPARATOR): The patients allocated to this group will receive metronidazole 400 mg t.i.d. for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).